Efficacy of Granisetron in the Antiemetic Control of Nonsurgical Intestinal Obstruction in Advanced Cancer: A Phase II Clinical Trial

Journal of Pain and Symptom Management

Volumn 37, Issue 2, 2009, Pages 259-270

  Tuca, Albert ^a   Roca, Rosa ^b   Sala, Carme ^c   Porta, Josep ^a   Serrano, Gala ^a   González Barboteo, Jesús ^a   Gómez Batiste, Xavier ^a  

^a Instituto Catalán   (Spain)

^b Hospital de Santa Caterina   (Spain)

^c Hospital de Sant Llàtzer Terrassa   (Spain)

Author keywords

5 HT3 receptor antagonists; Advanced cancer; antiemetics; granisetron; intestinal obstruction

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; CHLORPROMAZINE; DEXAMETHASONE; GRANISETRON; HALOPERIDOL; METHYLPREDNISOLONE; METOCLOPRAMIDE; MORPHINE; OCTREOTIDE; ONDANSETRON; OPIATE; SCOPOLAMINE BUTYL BROMIDE; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASTHENIA; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GYNECOLOGIC CANCER; HEADACHE; HUMAN; INTESTINE OBSTRUCTION; MALE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; RATING SCALE; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; FEMALE; GRANISETRON; HUMANS; INTESTINAL NEOPLASMS; INTESTINAL OBSTRUCTION; MALE; MIDDLE AGED; SPAIN; TERMINAL CARE; TREATMENT OUTCOME;

EID: 59649102439     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2008.01.014     Document Type: Article

References (54)

1. Ripamonti C. Management of bowel obstruction in advanced cancer patients. J Pain Symptom Manage 49 (1994) 193-200
2. Ripamonti C., De Conno F., Vantafridda V., et al. Management of bowel obstruction in advanced and terminal cancer patients. Ann Oncol 4 (1993) 15-21
3. Ripamonti C., Twycross R., Baines M., et al. Clinical practice recommendations for management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 9 (2001) 223-233
4. Feuer D.J., and Bradley K.E. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev 2 (2000) CD001219
5. Feuer D.J., and Bradley K.E. Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecologic and gastrointestinal cancers. Ann Oncol 10 (1999) 1035-1041
6. Miller G., Boman J., Shrier I., and Gordon P.H. Readmission for small-bowel obstruction in the early postoperative period: etiology and outcome. Can J Surg 45 (2002) 255-258
7. Parker M.C., and Baines M.J. Intestinal obstruction in patients with advanced malignant disease. Br J Surg 83 (1996) 1-2
8. Lund B., Hansen M., Lundvall F., et al. Intestinal obstruction in patients with advanced carcinoma of the ovaries treated with combination chemotherapy. Surg Gynecol Obstretics 169 (1989) 213-218
9. Rubin S.C., Hoskins W.J., Benjamin I., and Lewis J.L. Palliative surgery for intestinal obstruction in advanced ovarian cancer. Gynecol Oncol 34 (1989) 16-19
10. Tunca J.C., Buchler D.A., Mack E.A., et al. The management of ovarian-cancer-caused bowel obstruction. Gynecol Oncol 12 (1981) 186-192
11. Castaldo T.W., Petrilli E.S., Ballon S.C., and Lagasse L.D. Intestinal operations in patients with ovarian carcinoma. Am J Obstet Gynecol 139 (1981) 80-84
12. Piver M.S., Barlow J.J., Lele S.B., and Frank A. Survival after ovarian cancer-induced intestinal obstruction. Gynecol Oncol 13 (1982) 44-49
13. Ripamonti C., Panzeri C., Groff L., et al. The role of somatostatin and octreotide in bowel obstruction: pre-clinical and clinical results. Tumori 87 (2001) 1-9
14. Krebs H.B., and Goplerud D.R. Mechanical intestinal obstruction in patients with gynecologic disease: a review of 368 patients. Am J Obstet Gynecol 157 (1987) 577-583
15. Clarke-Pearson D.L., Chin N.O., DeLong E.R., et al. Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, and survival. Gynecol Oncol 26 (1987) 11-18
16. Beattie G.J., Leonard R., and Smyth J.F. Bowel obstruction in ovarian carcinoma: a retrospective study and review of the literature. Palliat Med 3 (1989) 275-280
17. Spears H., Petrelli N.J., Herrera L., and Mittelman A. Treatment of bowel obstruction after operation for colorectal carcinoma. Am J Surg 155 (1988) 383-386
18. Pictus D., Marx M.V., and Weyman P.J. Chronic intestinal obstruction: value of percutaneous gastrostomy tube placement. Am J Radiol 150 (1988) 295-297
19. Van Oojen B., van der Burg M.E.L., ASTh P., et al. Surgical treatment of gastric drainage only for intestinal obstruction in patients with carcinoma of the ovary or peritoneal carcinomatosis of other origin. Surg Gynecol Obstet 176 (1993) 469-474
20. Jong P., Sturgeon J., and Jamieson C.G. Benefit of palliative surgery for bowel obstruction in advanced ovarian cancer. Can J Surg 38 5 (1995) 454-457
21. Sun X., Li X., and Li H. Management of intestinal obstruction in advanced ovarian cancer: an analysis of 57 cases. Chung Hua Chung Liu Tsa Chih 17 (1995) 39-42
22. Redman C.W.E., Shafi M.I., Ambrose S., et al. Survival following intestinal obstruction in ovarian cancer. Eur J Surg Oncol 14 (1988) 383-386
23. Buther J.A., Cameron B.L., Morrow M., et al. Small bowel obstruction in patients with a prior history of cancer. Am J Surg 162 (1991) 624-628
24. Woolfson R.G., Jennings K., and Whalen G.F. Management of bowel obstruction in patients with abdominal cancer. Arch Surg 132 (1997) 1093-1097
25. Chan A., and Woodruff R.K. Intestinal obstruction in patients with widespread intra-abdominal malignancy. J Pain Symptom Manage 7 (1992) 339-342
26. Ripamonti C.I., Easson A.M., and Gerdes H. Management of malignant bowel obstruction. Eur J Cancer 44 8 (2008) 1105-1115
27. Ventafridda V., Ripamonti C., Caraceni A., et al. The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori 76 (1990) 389-393
28. Ripamonti C., Mercadante S., Groff L., et al. Role of octreotide, scopolamine butylbromide and hydration in symptom control of patients with inoperable bowel obstruction having a nasogastric tube: a prospective, randomized clinical trial. J Pain Symptom Manage 19 (2000) 23-34
29. Mercadante S., Ripamonti C., Casuccio A., et al. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 8 (2000) 188-191
30. De Conno F., Caraceni A., Zecca E., et al. Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manage 6 (1991) 484-486
31. Mercadante S., Kargar J., and Nicolosi G. Octreotide may prevent definitive intestinal obstruction. J Pain Symptom Manage 13 (1997) 352-355
32. Mulvihill S.J., Pappas T.N., Fonkalsrud E.W., and Debas H.T. The effect of somatostatin on experimental intestinal obstruction. Ann Surg 207 (1988) 169-173
33. Mercadante S., Ferrera P., Villari P., and Marrazzo A. Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manage 28 (2004) 412-416
34. Lau P.W., and Lorentz T.G. Results of surgery for malignant bowel obstruction in advanced, unresectable, recurrent colorectal cancer. Dis Colon Rectum 36 (1993) 61-64
35. Helyer L., and Easson A.M. Surgical approaches to malignant bowel obstruction. J Support Oncol 6 3 (2008) 105-113
36. Baines M., Oliver D.J., and Carter R.L. Medical management of intestinal obstruction in patients with advanced malignant disease. Lancet 2 (1985) 990-993
37. Mercadante S., Spoldi E., Caraceni A., Naddaloni S., and Simoneti M.T. Octeotride in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med 7 (1993) 295-297
38. del Gilglio A., Soares H.P., Caparroz C., and Castro P.C. Granisteron is equivalent to ondansetron for prophylaxis of chemotherapy induced nausea and vomiting, results of meta-analysis of randomized clinical trials. Cancer 89 (2000) 2301-2308
39. Henzi J., Walder B., and Tramer M.R. Dexamethasone for prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg 90 (2000) 186-194
40. Figueredo E., and Canosa L. Prophylactic ondansetron for postoperative emesis, meta-analysis of its effectiveness in patient with previous history of postoperative nausea and vomiting. Eur J Anaesthesiol 16 (1999) 556-564
41. Figueredo E., and Canosa L. Prevention or treatment of postoperative vomiting using ondansetron? A mathematical assessment. J Clin Anesth 11 (1999) 24-31
42. Tramer M.R., Reynolds D.J., Stoner N.S., Moore R.A., and Mc Quay H.J. Efficacy of antagonists 5 HT3 receptors in radiotherapy-induced nausea and vomiting, a quantitative systematic review. Eur J Cancer 34 (1998) 1836-1844
43. Hutchinson S.M.W., Beattie G., and Shearing C.H. Increased serotonin excretion in patients with ovarian carcinoma and intestinal obstruction. Palliat Med 9 (1995) 67-68
44. Jiménez García A., Balongo García R., Alconero F.F., et al. Intestinal wall damage in simple ileus in rabbits: immune modulator role of somatostatin. Hepatogastroenterology 58 (2004) 1030-1036
45. Mulvenna P.M., and Regnard C.F. Subcutaneous ondansetron [letter]. Lancet 339 (1992) 1059
46. Nicholson G.A., Evans C., and Mansi J. Ondansetron in intractable nauseas and vomiting. [letter]. Lancet 339 (1992) 490
47. Cole M.C., Robinson F., Harvey L., Trethowan K., and Murdoch V. Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in patients with advanced cancer. J Pain Symptom Manage 9 (1994) 48-50
48. Mercadante S., Sarpio M., and Seretta R. Ondansetron in nausea and vomiting induced by spinal morphine. J Pain Symptom Manage 16 (1998) 259-262
49. Currow D.C., Coughlan M., Fardell B., and Cooney N.J. Use of ondansetron in palliative medicine. J Pain Symptom Manage 13 (1997) 302-307
50. Tuca A. Effectiveness of selective antagonist of 5 HT3 receptors in nausea and vomiting not induced by cancer chemotherapy. [Spanish]. Med Pal 7 (2000) 62-64
51. Mystakidou K., Befon S., Liossi C., and Viachos L. Comparison of the efficacy and safety of tropisetron, metoclopramide and chlorpromazine in the treatment of emesis associated with far advanced cancer. Cancer 83 (1998) 1214-1223
52. Lindley C., and Blower P. Oral serotonin type 3-receptor antagonist for prevention of chemotherapy-induced emesis. Am J Health Syst Pharm 15 (2000) 1685-1697
53. Goyal R.K., and Hirano I. Enteric nervous system. N Engl J Med 334 17 (1996) 1106-1115
54. Cubeddu L.X., Hoffman I.S., Fuenmayor N.T., and Finn A.L. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 322 (1990) 810-816